Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in request metadata) on September 12, 2016. The filing serves to furnish an updated investor presentation (Exhibit 99.1) intended for use at the 18th Annual Rodman & Renshaw Global Investment Conference held in New York, NY. Stephen From, President and CEO, presented the information on the filing date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation and does not contain audited financial statements or a financial results summary.
Material Changes
No material changes to financial performance or operations are reported in the text of this filing. The document solely references the distribution of an investor presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an updated investor presentation for use at an investment conference.
Legal Disclaimers: The information furnished, including Exhibit 99.1, is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The Company explicitly states it does not assume any obligation to update the information in the future.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Investor Presentation) for specific operational updates or financial projections, as the 8-K text itself contains no data.
- Confirm the company name discrepancy: The filing header lists "EyeGate Pharmaceuticals, Inc." while the request metadata lists "Kiora Pharmaceuticals Inc."
- Note that the information provided is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Check for subsequent filings to see if the Company has updated the information presented on September 12, 2016, as they have disclaimed an obligation to do so.